| 注册
首页|期刊导航|中国药业|他汀类调脂药与其他药物联用致不良反应临床分析

他汀类调脂药与其他药物联用致不良反应临床分析

姚晖

中国药业2017,Vol.26Issue(6):69-71,3.
中国药业2017,Vol.26Issue(6):69-71,3.DOI:10.3969/j.issn.1006-4931.2017.06.021

他汀类调脂药与其他药物联用致不良反应临床分析

Clinical Analysis of Adverse Drug Reaction Induced by Statins Combined with Other Drugs

姚晖1

作者信息

  • 1. 西南医科大学附属医院,四川泸州 646000
  • 折叠

摘要

Abstract

Objective To investigate the features of adverse drug reaction(ADR)induced by statins combined with other drugs,in order to provide reference for clinical rational drug use. Methods The clinical data of 78 patients with ADRs caused by statins combined with other drugs in the hospital from June 2011 to June 2016 were reviewed and analyzed. Results The main manifestations of the ADRs were muscle toxicity,liver toxicity,digestive discomfort,respiratory discomfort,et al,in which muscle toxicity and liver toxicity were the most common ADRs. The incidence rate of rhabdomyolysis was 20. 51%,which was significantly higher than that of the other ADRs (p < 0. 05). The incidence rates of ADR induced by Simvastatin and Atorvastatin were 44. 87% and 28. 21%,respectively,which were significantly higher than the other statins (p < 0. 05). The incidence of ADR was the highest(30. 77%)when the statins combined with antihypertensive drugs and anti-myocardial drugs,the incidence of ADR was the second ( 20. 51% ) when statins combined with lipid-lowering drugs. Conclusion The ADR rate is relatively high when statins,especially Simvastatin and Atorvastatin combined with anti-hypertensive,anti-myocardial and lipid-lowering drugs,and the main manifestations of the ADRs are liver toxicity and muscle toxicity. The standardized and rational medication regimen should be made based on the clinical characteristics of patients and the type of drug in the clinical use of statins,in order to minimize the occurrence of the ADRs.

关键词

他汀类药物/联合用药/药品不良反应/临床分析/合理用药

Key words

statins/drug combination/adverse drug reaction/clinical analysis/rational drug use

分类

医药卫生

引用本文复制引用

姚晖..他汀类调脂药与其他药物联用致不良反应临床分析[J].中国药业,2017,26(6):69-71,3.

中国药业

OACSTPCD

1006-4931

访问量0
|
下载量0
段落导航相关论文